0001104659-19-040007.txt : 20190712 0001104659-19-040007.hdr.sgml : 20190712 20190712062850 ACCESSION NUMBER: 0001104659-19-040007 CONFORMED SUBMISSION TYPE: FWP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20190712 DATE AS OF CHANGE: 20190712 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENMAB A/S CENTRAL INDEX KEY: 0001434265 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: FWP SEC ACT: 1934 Act SEC FILE NUMBER: 333-231777 FILM NUMBER: 19952033 BUSINESS ADDRESS: STREET 1: TOLDBODGADE 33 CITY: 1253 COPENHAGEN K STATE: G7 ZIP: 00000 MAIL ADDRESS: STREET 1: TOLDBODGADE 33 CITY: 1253 COPENHAGEN K STATE: G7 ZIP: 00000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GENMAB A/S CENTRAL INDEX KEY: 0001434265 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: FWP BUSINESS ADDRESS: STREET 1: TOLDBODGADE 33 CITY: 1253 COPENHAGEN K STATE: G7 ZIP: 00000 MAIL ADDRESS: STREET 1: TOLDBODGADE 33 CITY: 1253 COPENHAGEN K STATE: G7 ZIP: 00000 FWP 1 a19-3729_9fwp.htm FWP

 

Issuer Free Writing Prospectus dated July 12, 2019

Filed Pursuant to Rule 433

Relating to the Preliminary Prospectus dated July 9, 2019 and

Registration Statement No. 333-231777

 

 

This free writing prospectus relates to the U.S. initial public offering of American Depositary Shares (“ADSs”) of Genmab A/S (the “Company”), each representing one-tenth of one of the Company’s ordinary shares. This free writing prospectus updates and supplements the information in the preliminary prospectus dated July 9, 2019 (the “Preliminary Prospectus”) that was included in Amendment No. 1 to the Registration Statement on Form F-1 (the “Registration Statement”) relating to this offering of the Company’s ADSs and should be read together with the Preliminary Prospectus.  The Preliminary Prospectus may be accessed through the following link:  https://www.sec.gov/Archives/edgar/data/1434265/000104746919004052/a2238946zf-1a.htm. The Company expects to file an amendment to the Preliminary Prospectus prior to effectiveness of the Registration Statement to add the following additional disclosure in the “Recent Developments” section of the Prospectus Summary on page 12 of the Preliminary Prospectus:

 

Recent Developments

 

Entry into a DuoBody License Agreement with BliNK Biomedical

 

On July 12, 2019, we entered into an agreement with BliNK Biomedical for an exclusive commercial license to certain antibodies targeting CD47 for potential development and commercialization into novel bispecific therapeutics created via our proprietary DuoBody technology.  Under the terms of the agreement, we will pay BliNK Biomedical an upfront fee of $2.25 million. BliNK Biomedical is also eligible to receive up to approximately $200.0 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.

 

The Company has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering.  You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.  Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it from: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email:  dg.prospectus_requests@baml.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone: 1-877-821-7388, or by email: Prospectus_Department@Jefferies.com.

 


GRAPHIC 2 g37299bgi001.jpg GRAPHIC begin 644 g37299bgi001.jpg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